News By Tag
News By Place
Follow on Google News
Excitement Amongst HCP's about New Multiple Sclerosis Drug Treatments
By: Vivisum Partners, LLC
According to Multiple Sclerosis Clinical Pipeline Analysis, Evobrutinib is one of the most familiar of the pipeline treatments, however, the emerging MS Treatment Vidofludimus Calcium, while less familiar, is expected to be superior on efficacy and safety according to surveyed neurologists. Escalation treatments in the new MS landscape are not the only facet of the market that is expected to be shaken up. Orelabrutinib may compete with therapies typically used earlier in the algorithm, such as Gilenya and Tecfidera.
There is no stand-out competitor for Vidofludimus Calcium, but the largest percentage of HCPs expect it to compete with Tecfidera, Gilenya, or Aubagio. A majority of neurologists expect Vidofludimus Calcium's tolerability to be slightly better than the competition. Evobrutinib, though more familiar, is second to last in the ranking of new MS drug treatments with the highest excitement.
"More than half of surveyed neurologists are familiar with Evobrutinib, and about half are excited about its prospects as a viable MS treatment.,"
Multiple Sclerosis Clinical Pipeline Analysis, published in October 2022 by Vivisum Partners, examines each MS pipeline drug's strengths and weaknesses across six key clinical attributes:
The market research contained in Multiple Sclerosis Clinical Analysis, found at https://vivisumpartners.com/
ABOUT VIVISUM PARTNERS, LLC
Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.
Account Email Address Account Phone Number Disclaimer Report Abuse